

May 18, 2009

## ASCO Snapshot: Lung Cancer

Event: American Society of Clinical Oncology, May 29—June 2,



### Market Leaders

Roche (OTC:RHHBY)/OSI (NASDAQ:OSIP): Tarceva: 2008 Sales USD 1050m

[OSI/Genentech: Tarceva will need to show 'staggering' PFS benefit greater than 2-3 months to compete with Eli Lilly's Alimta - analysis \(Pharmawire\)](#)

[OSI's Tarceva and Eli Lilly's Alimta will be adopted in maintenance NSCLC if a two to three month PFS benefit is shown in trials, physicians say \(Pharmawire\)](#)

[OSI Pharmaceuticals: Tarceva ATLAS study shows positive results, but survival benefit of maintenance therapy in lung cancer remains to be determined - analysis \(Pharmawire\)](#)

[OSI Pharma: SATURN trial testing Tarceva as maintenance therapy should benefit limited patient population with non-small cell lung cancer in the US \(Pharmawire\)](#)

Roche (OTC:RHHBY)/Genentech: Avastin: 2008 Sales USD 4453m

[Genentech's Avastin for non-small cell lung cancer does not hold advantage in halting distant tumor recurrences, physicians say \(Pharmawire\)](#)

[Genentech's Avastin and Lilly's Erbitux: combination Phase III SWOG trial for treatment of NSCLC faces significant hurdles - analysis \(Pharmawire\)](#)

Eli Lilly (NYSE:LLY): Alimta: 2008 Sales USD 1155

Eli Lilly (NYSE:LLY)/ImClone: Erbitux

[Eli Lilly: Erbitux unlikely to be widely adopted in NSCLC despite potential approval as mixed-results from FLEX and BMS-099 trials still linger \(Pharmawire\)](#)

[Imclone's Erbitux will have to focus on patient selection in lung cancer, but sample collection will be "very difficult," lead investigator says \(Pharmawire\)](#)

Novartis(NYSE:NVS)/Antisoma (LON:ASM): ASA-404

[Antisoma, Novartis' ASA404 may show greater benefit if studied with cisplatin and gemcitabine, physicians say \(Pharmawire\)](#)

[Antisoma and Novartis: ASA404's actions on tumor blood vessels may cause side effect of bleeding similar to Avastin, physicians say \(Pharmawire\)](#)

[Antisoma and Novartis' ASA404 should show overall survival benefit to garner FDA/EMEA approval in NSCLC, physicians say \(Pharmawire\)](#)



### Unpartnered Targets in Development

Peregrine Pharmaceuticals (NASDAQ:PPHM): bavituximab: market cap USD 108.58m

[Peregrine Pharmaceuticals reports positive preliminary data from Phase II bavituximab lung cancer trial](#)

Cell Therapeutics (NASDAQ:CTIC): PTG307: market cap USD 549.69m

[Cell Therapeutics has no present plans for additional financing, focused on partnering oncology drug pixantrone, CEO says \(Pharmawire\)](#)

Cyclacel (NASDAQ:CYCC): seliciclib: market cap USD 17.99m

[Cyclacel's seliciclib comes under physician scrutiny due to elevated liver enzymes in non-small cell lung cancer trial - analysis \(Pharmawire\)](#)

Tragara Pharmaceuticals (private): TG01: Raised USD 40m in Series A Financing March 2007

Gemin X (private): Obatoclax: Raised USD 38m in Series C Financing June 2008

Endocyte (private): EC145: Secured USD 15m Venture Debt Facility January 2008